SRRK stock icon

Scholar Rock
SRRK

$9.31
1.09%

Market Cap: 743M

 

About: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Employees: 150

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,787% more call options, than puts

Call options by funds: $8.96M | Put options by funds: $475K

135% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 17

17% more funds holding

Funds holding: 132 [Q4 2023] → 155 (+23) [Q1 2024]

9% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 46

1% less capital invested

Capital invested by funds: $1.51B [Q4 2023] → $1.5B (-$17.7M) [Q1 2024]

3.43% less ownership

Funds ownership: 111.66% [Q4 2023] → 108.23% (-3.43%) [Q1 2024]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 3 (-1) [Q1 2024]

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$20
115%
upside
Avg. target
$28
200%
upside
High target
$31
233%
upside

10 analyst ratings

10 positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andres Maldonado
222%upside
$30
Buy
Reiterated
25 Jun 2024
BMO Capital
Etzer Darout
233%upside
$31
Outperform
Maintained
13 Jun 2024
HC Wainwright & Co.
Andres Maldonado
222%upside
$30
Buy
Reiterated
4 Jun 2024
HC Wainwright & Co.
Andres Maldonado
222%upside
$30
Buy
Reiterated
23 May 2024
HC Wainwright & Co.
Andres Maldonado
222%upside
$30
Buy
Reiterated
8 May 2024

Financial journalist opinion

Based on 3 articles about SRRK published over the past 30 days